PanGenetics' CD40 enters Ph I trial

19 October 2008

Dutch drug developer PanGenetics BV has received formal regulatory approval to initiate clinical evaluation of its CD40 antagonist antibody, PG102. The multicenter trial in Hungary and Serbia will recruit patients with active psoriatic arthritis, and is designed as a double-blind, placebo-controlled, single ascending-dose study.

The primary objective of the Phase I program is to evaluate the safety and tolerability of PG102. The design includes evaluation of pharmacodynamic and clinical parameters, to provide further insight into the immuno-modulatory mechanisms of PG102. The trial will commence in the next few weeks and the results, which include an extended follow-up period, are expected in the fourth quarter of 2009.

A precursor of this antibody was previously successfully evaluated in an open label study in Crohn's disease patients. The experience from this earlier work, combined with a comprehensive preclinical package, provided the basis for the clinical trial authorizations.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight